114 Chapter 5 adjusted 6.7% (-3.6―18.2) 0.2681 4.8% (15―6.6) 0.4348 0.7617 Angiopoietin-1 unadjusted -3.7% (-18.3―13.5) 0.6517 -11.6% (-34.2―7.2) 0.2671 0.4243 adjusted 0.1% (-14.8―17.6) 0.9895 -7.9% (-29.2―10.0) 0.4348 0.3954 Angiopoietin-2 unadjusted 17.7% (4―33.1) 0.0308 33.8% (42.3―24.1) <0.0001 <0.0001 adjusted 16.4% (3.1―31.3) 0.0444 32.8% (41.3―23.1) <0.0001 <0.0001 s-Tissue factor unadjusted 10.1% (2―18.8) 0.0334 10.8% (17.9―3.1) 0.0108 0.5754 adjusted 6.5% (-0.8―14.3) 0.1534 8% (14.8―0.6) 0.0506 0.5409 D-dimer unadjusted 8.6% (-0.7―18.8) 0.1116 7.4% (16.3―2.5) 0.1773 0.9023 adjusted 8.4% (-0.8―18.3) 0.1534 7.3% (16.1―2.4) 0.1702 0.9348 BH Benjamini Hochberg adjustment for multiple testing. The coefficient represents a relative change of the plasma biomarker concentration of cases compared to controls. All biomarkers were log-transformed, and backtransformed for interpretability to obtain differences between cases and controls in %. Interaction indicates if there is a different biomarker trajectory from baseline to onset of ICU-acquired pneumonia for cases was compared to controls (not corrected for multiple testing). Models were adjusted for following potential confounders: site of enrollment, age, sex, body mass index, primary reason for ICU admission, Charlson Comorbidity Index, immunodeficient as chronic comorbidity, Acute Physiology and Chronic Health Evaluation IV score.
RkJQdWJsaXNoZXIy MTk4NDMw